Ashling Wahner is an Editor at CURE Media Group. She specializes in medicine and healthcare, focusing on topics such as oncology, immunotherapy, and medical technology. Ashling's work has been featured in prominent publications including Urology Times, Diagnostic Imaging®, and Oncology Nursing News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ashling Wahner's articles predominantly focus on healthcare and pharmaceuticals, specifically cancer research, FDA approvals, targeted therapies, treatment efficacy, and clinical trials. Considering her coverage attributes of citing data and including expert commentary in over 80% of the articles analyzed, she would likely be interested in pitches that provide access to new or exclusive data related to developments in cancer research and pharmaceuticals.
Experts who can offer deep insights into the latest trends in these fields may find success when reaching out to Ashling. Additionally, individuals with firsthand knowledge about specific treatments or clinical trials could also capture her interest.
This information evolves through artificial intelligence and human feedback. Improve this profile .
PANOVA-3 Trial Key Takeaways In this pivotal phase 3 trial of patients with unresectable locally advanced pancreatic adenocarcinoma, adding
Key Takeaways FDA cleared lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive mHSPC in combination with ADT, extending radioligand therapy into the hormone-sensitive metastatic setting. PSMAddition showed a 28% reduction in progression or death versus ARPI plus ADT alone (HR 0.72; 95% CI, 0.58-0.90). Updated efficacy strengthened rPFS benefit (HR 0.67; 95% CI, 0.55-0.82) and suggested an overall survival trend (HR 0.80; 95% CI, 0.63-1.01). Overall survival will require longer follow-up before final analysis, but current results support earlier treatment intensification in PSMA-selected metastatic disease. SHOW MORE
By: Ashling Wahner
Andrew H. Ko, MD, discusses how TTFields works and data that supported the FDA approval of Optune Pax for patients with pancreatic cancer.
By: Ashling Wahner
Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Divesiran significantly increased the proportion of clinical responders vs placebo in phlebotomy-dependent polycythemia vera.
By: Ashling Wahner
Key Takeaways TNFR2 signaling promotes tumor proliferation and TME immune suppression; targeting TNFR2 can deplete TNFR2+ Tregs, remodel myeloid cells, and restore CD8+ cytotoxic antitumor immunity. In relapsed/refractory CTCL/PTCL, BI-1808 monotherapy achieved 40% ORR (1 CR, 5 PR; n=15) with 93% DCR, including responses in extensively pretreated stage IV disease. Combining BI-1808 with pembrolizumab increased ORR to 50% in a small lymphoma cohort (n=8) but substantially worsened grade ≥3 TRAEs (40% vs 9% monotherapy). In ovarian cancer, BI-1808 monotherapy yielded 41% DCR (n=17), while BI-1808 plus pembrolizumab produced 24% ORR and 56% DCR with median PFS 10.2 months. Next-step development emphasizes optimizing combinations with acceptable incremental toxicity, refining response assessment via ctDNA, and expanding TNFR2 inhibition into CRC, AML, and breast cancer settings. SHOW MORE
By: Ashling Wahner
Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.
By: Ashling Wahner
T-DXd in HER2+ Early Breast Cancer: Highlights In the neoadjuvant DESTINY-Breast11 trial, T-DXd followed by THP significantly improved pCR
Frontline Sacituzumab Govitecan and Dato-DXd: Expert Insights Both ADCs represent some of the first targeted therapies made available in the frontline for TNBC.
